Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $120
Jefferies Maintains Exact Sciences(EXAS.US) With Buy Rating, Maintains Target Price $75
Exact Sciences Analyst Ratings
Truist Financial Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Announces Target Price $120
Buy Rating on Viking Therapeutics: A Strategic Opportunity Amid Market Overreaction
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
Alnylam Pharmaceuticals Price Target Raised to $280.00/Share From $248.00 by JP Morgan
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
J.P. Morgan Maintains Alnylam Pharmaceuticals(ALNY.US) With Hold Rating
Evercore ISI Raises Price Target on AbbVie to $192 From $180, Keeps Outperform Rating
Regeneron Pharmaceuticals Analyst Ratings
AbbVie Analyst Ratings
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,242
Piper Sandler Maintains AbbVie(ABBV.US) With Buy Rating, Raises Target Price to $209
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Gilead Sciences: A Balanced Hold Rating Amidst Growth Prospects and Market Challenges
Analysts' Opinions Are Mixed on These Healthcare Stocks: Gilead Sciences (GILD) and Premier (PINC)
Wells Fargo Maintains Gilead Sciences(GILD.US) With Hold Rating, Maintains Target Price $78
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $375
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,200